Background and Objectives: Parkinson’s disease (PD) is frequently associated with postural instability, including camptocormia, an involuntary anterior flexion of the thoracolumbar spine. This retrospective observational pilot study evaluated the effects of a postural group rehabilitation protocol on the stabilometric parameters, depressive symptoms, and quality of life in PD patients with camptocormia, and whether gains were maintained during a subsequent two-month period after completion of supervised group rehabilitation, during which patients were provided with a general home-based exercise program. Materials and Methods: Forty patients with idiopathic PD (Hoehn and Yahr II–III) were assessed at baseline (T0), after two months of twice-weekly rehabilitation (T1). At T2, only stabilometric follow-up was performed after two months without group exercise for 38 patients. Outcomes included SPPB, Tinetti, Berg Balance Scale, Hamilton Depression Rating Scale, PDQ-39, occiput-to-wall distance and stabilometric analysis. Results: At T1, Hamilton scores decreased from 11.44 ± 4.59 to 3.33 ± 3.04 and PDQ-39 from 82.22 ± 22.36 to 69.72 ± 16.54 (both p < 0.001). Occiput-to-wall distance improved significantly in three of six positions. The EO/EC Perimeter Ratio decreased significantly from T0 to T1 (p = 0.016). Between T1 and T2, EO Perimeter continued improving (p = 0.010), whereas the Perimeter Ratio worsened (p = 0.046), and EC Ellipse area, though non-significant, increased rather than decreased. Conclusions: A two-month protocol was followed by apparent improvements in depression, quality of life, postural alignment, and selected stabilometric parameters. After discontinuation, some parameters appeared to improve while others seemed to worsen, suggesting these effects may not be sustained with uniformity. These preliminary findings should be confirmed with an expanded sample size in larger studies.

Temporomandibular disorders (TMDs) represent a heterogeneous group of conditions, including myogenous and arthrogenous, with a significant impact on quality of life. Botulinum toxin type A (BoNT-A) has been proposed as a therapeutic option, particularly for patients with refractory myogenous TMD and bruxism. This systematic review aimed to evaluate the clinical effectiveness of BoNT-A in the management of TMDs overall and bruxism, with particular focus on myogenous TMDs compared to placebo and non-surgical treatments. RCTs published between 2020 and 2025 were identified through PubMed, Scopus, and Google Scholar. Overall, 15 RCTs involving 797 participants were included. The available evidence suggests potential benefits of BoNT-A, particularly in patients with localized myofascial pain, myogenous TMD, or marked masticatory muscle hyperactivity. Interpretation of the findings is limited by substantial heterogeneity in treatment protocols, toxin dosage, diagnostic criteria, outcome measures, and follow-up duration. Current evidence does not support the routine use of BoNT-A as a first-line treatment for TMDs overall. Instead, BoNT-A may represent an adjunctive or second-line option for selected patients with myogenous TMD, localized myofascial pain, or marked masticatory muscle hyperactivity who do not adequately respond to conventional noninvasive treatment. Larger and methodologically rigorous RCTs are needed to establish appropriate indications, duration of treatment effects, and long-term safety across different TMD subtypes.